22 January 2015
A new platform to rapidly tailor drug combinations to treat resistant forms of lung cancer has been developed by researchers at Massachusetts General Hospital.
Lead researcher Alice Shaw said: "If we understand what makes tumors resistant, then we can design better drug combinations - ones that not only attack the cancer but also cut off its escape routes. The current approach doesn't do the job effectively."
A new method of testing drug combinations has been developed throughout the research, which entails growing cancer cells taken from the patient in the laboratory, and using them to test potential treatments. Dr Shaw says it revealed effective combinations that would not have been found through standard testing.
This approach represents a big step forward in the field of personalised medicine and may lead to more positive outcomes for patients with resistant cancers.
The research was published in the December edition of Science.
Posted by Phillip Briggs
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.
or Spire Healthcare.